Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2022 16:05 ET | Source: Morphic Therapeutic

Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Saturating receptor occupancy at 100 and 200 mg BID doses Statistically significant effects on key lymphocyte subsets WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq:...
October 24, 2022 08:00 ET | Source: Morphic Therapeutic

Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections

WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
November 15, 2021 09:05 ET | Source: Morphic Therapeutic

Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Annual Meeting

αvβ8 inhibition demonstrates efficacy in a cancer model refractory to radiation and checkpoint inhibition Data provide increased rationale to explore integrin inhibition as a component in combination...